As part of the 39th Annual Meeting & Pre-Conference Programs (SITC 2024), the SITC Tumor Infiltrating Lymphocytes (TIL) Symposium pre-conference program provides an opportunity for an in-depth discussion on a specific topic in the field of IO. This program will provide an overview of the path to approval for TIL therapy, current clinical management, and the impact of recent FDA-approved therapies while exploring next generation TIL and innovative pre-clinical development. Through didactic presentations and panels to engage an interdisciplinary audience, the program aims to bring the field together to educate and promote the continued utilization and development of TIL therapies to address hurdles in cancer immunotherapy. The program can be registered for and accessed virtually HERE.
#SITC2024